Emerging markers such as podoplanin (D2-40) and androgen receptor (AR) have been explored in distinguishing eccrine carcinoma subtypes, though their utility in SEDC remains unclear [37,38,39]. This evidence concerns the gene PDPN and spondyloepiphyseal dysplasia congenita.